We argue that there is an emergent trend of businesses and industries that move beyond optimizing the organization's individual performance by mitigating negative environmental and social impacts, to fundamentally restructuring and rethinking existing businesses in light of broader societal changes. Arguably, the frontrunner businesses that orient themselves towards sustainable market transitions develop a competitive advantage by co-creating these sustainable markets and on the short term develop renewed ambition and enthusiasm. By means of the transition framework, we argue that the fundamental societal changes emerging lead to a new phase in corporate responsibility, implying fundamental transitions within businesses. Based on this perspective and the transition management approach we explore how businesses might proactively engage with sustainability transitions in their direct context and link these to internal business transitions. We illustrate this framework of business transition management in a number of interlinked activities based on an experimental participatory case study of the transition in the Dutch roof sector.

Q1

What is the cause of Pott's103140 disease?

Q2

One thing that often baffles me is that patients with systemic lupus

erythematosus often suffer recurrent thrombosis due to lupus

anticoagulants (antiphospholipid syndrome). How can an anticoagulant

cause thrombosis?

Q3

Are elevated homocysteine levels an independent risk factor for

progression of systemic lupus erythematosus (SLE)/scleroderma? Kindly

suggest some references if possible.

Q4

1. What are the indicators of remission in systemic lupus erythematosus

(SLE)? Is it the normalization of erythrocyte sedimentation rate (ESR)

and the disappearance of antinuclear antibodies (ANA) and other

antibodies, or is it clinical improvement?

2. During remission of SLE, do ANA and other antibodies disappear?

Q5

When should the use of cyclophosphamide in systemic lupus

erythematosus (SLE) be commenced? What is the correct and safe dosage

of cyclophosphamide?

Q6

1. Given the benefits of dexamethasone, which lacks any

mineralocorticoid activity, why is this not prescribed in your book for

diseases that require long-term steroid therapy, such as systemic lupus

erythematosus or giant cell arteritis?

2. Does dexamethasone have more serious adverse effects than

prednisolone? Why is it not generally preferred?

Q7

Would an elevated C-reactive protein (CRP) level, in association with a

high erythrocyte sedimentation rate (ESR) and in the absence of infection

and serositis, exclude the diagnosis of systemic lupus erythematosus?

Q8

How do steroids precipitate a crisis in patients with systemic sclerosis?

Q9

Are neck and face muscles commonly affected in poly- and

dermatomyositis? Does this differ from the muscles that are affected with

myasthenia gravis?

Q10

1. In dermatomyositis, what is the shawl sign?

2. How frequently is dermatomyositis associated with Gottron's papules?